Franchise killer: Are Regeneron and Sanofi about to get handed their walking papers on PCSK9?
One top analyst believes that the Medicines Company may soon be in a position to do what years of payer resistance to Regeneron and Sanofi’s would-be PCSK9 blockbuster Praluent has so far failed to do:
Kill it.
So here’s the reasoning, and it’s compelling.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.